Company intelligence / Profile preview

MindX Sciences

Indianapolis, Indiana, United States

Ownership: Private
Development stage: Preclinical

Overview

MindX Sciences has developed blood-based biomarker tests that objectively assess mental health conditions such as depression and suicide risk. Their technology enables more precise matching of patients to medications or nutraceuticals. Clinical reports suggest the tests have improved treatment outcomes by enabling personalized therapy selection after failed standard approaches. The company’s digital tools are also being piloted in hospital settings in the US and UK

Therapeutic areas: PsychiatryNeurology
Modalities: Blood biomarker-based diagnostics (liquid biopsy)Digital health tools (apps)Companion diagnostics
Industry: Molecular Diagnostics

Partnerships

Indiana University School of Medicine/IP licensing partnerHospitals in Indianapolis, California & United Kingdom piloting programs

Beyond the preview

Go deeper on MindX Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MindX Sciences.

Explore the full profile